The latest issue of "Lancet · Oncology" published a study by China Ke Xueyuan Academy of Sciences , Zhongshan Hospital, Fudan University, Dean of Fan Jia study led
Research led by the dean of the Academy of Sciences .
Research recognized by the international oncology community
Research recognized by the international oncology community The study showed that as of August 15, 2020, the median follow-up time for both groups was 10 months
Fan Jia said that the combined treatment plan provides the world's largest comparison of immunotherapy and traditional targeted therapy for patients with hepatitis B-related liver cancer, bringing new hope to the treatment of hepatitis B-related liver cancer patients worldwide
Liver cancer is one of the most common malignant tumors of the digestive system worldwide.
Immune cells are reactivated to fight cancer
Immune cells are reactivated to fight cancer During the interview, the reporter learned that Sintilimab is a PD-1 inhibitor that has attracted much attention in the field of tumor immunotherapy
Bevacizumab is an angiogenesis inhibitor.
China Kexue Yuan academician , national drug created special technology division vice president Chen Kaixian, said the letter Dealey monoclonal antibody injection and bevacizumab injection by the letter of biopharmaceutical development, new drug development projects for the major national achievements
Academician of the Academy of Sciences It is reported that the above two drugs have been included in the national medical insurance catalog
Related paper information: https://doi.
https://doi.
org/10.
1016/S1470-2045(21)00252-7
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
